William Blair analyst Matt Phipps initiated coverage of Climb Bio (CLYM) with an Outperform rating and no price target The firm cites the potential of the company’s CD19 antibody, budoprutug, which is being developed across a range of autoimmune indications, for the rating. The simplicity of a monoclonal antibody will be attractive for community physicians who treat most autoimmune patients, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLYM: